Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker (Q37033656)

17 August 2017

1 reference

title

Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker (English)

1 reference

rel-(αR,α′R,2R,2′S)-nebivolol

17 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

L Michael Prisant

1

1 reference

17 August 2017

14 December 2007

1 reference

The Journal of Clinical Pharmacology

17 August 2017

1 reference

17 August 2017

48

1 reference

17 August 2017

2

1 reference

17 August 2017

225-239

1 reference

Beta-adrenergic blocking drugs in the treatment of hypertension

17 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Expert consensus document on beta-adrenergic receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Cardioprotection: the role of beta-blocker therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Clinical relevance of pharmacokinetic differences between beta blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Pharmacologic aspects of intrinsic sympathomimetic activity in beta-blocking drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Selective versus nonselective beta adrenoceptor antagonists in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Beta-blockers and central nervous system side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Lipophilicity, hydrophilicity, and the central nervous system side effects of beta blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Membrane stabilizing activity and beta-adrenoceptor antagonist-induced bradycardia in conscious dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Membrane stabilizing, anti-oxidative interactions of propranolol and dexpropranolol with neutrophils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

beta-Blockers in hypertension: is carvedilol different?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Short-term and long-term hemodynamic and clinical effects of metoprolol alone and combined with amlodipine in patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Heart rate dependency of cardiac performance in heart failure patients treated with metoprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Pharmacology of nebivolol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Nebivolol in the management of essential hypertension: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

A dose-response trial of nebivolol in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Nebivolol: new therapy update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Nebivolol: a third-generation beta-adrenergic blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Pharmacogenetics of antihypertensive drug responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Pharmacogenetics of antihypertensive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

A comparison of the beta1-selectivity of three beta1-selective beta-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Hemodynamic and beta-adrenergic receptor adaptations during long-term beta-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Nebivolol is devoid of intrinsic sympathomimetic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Effects of the selective beta 1-adrenoceptor antagonist, nebivolol, on cardiovascular parameters in the pithed normotensive rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Nitric oxide mediated venodilator effects of nebivolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Beta-blockade with nebivolol enhances the acetylcholine-induced cutaneous vasodilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Nebivolol: a selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Involvement of the beta3 adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Nebivolol induces calcium-independent signaling in endothelial cells by a possible beta-adrenergic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Estrogen receptor-mediated vascular responsiveness to nebivolol: a novel endothelium-related mechanism of therapeutic vasorelaxation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Nebivolol Prevents Vascular NOS III Uncoupling in Experimental Hyperlipidemia and Inhibits NADPH Oxidase Activity in Inflammatory Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Antioxidant activity of nebivolol in the rat aorta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Nebivolol decreases systemic oxidative stress in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Effects of nebivolol on human platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Markedly reduced effects of (-)-isoprenaline but not of (-)-CGP12177 and unchanged affinity of beta-blockers at Gly389-beta1-adrenoceptors compared to Arg389-beta1-adrenoceptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Racial differences in nitric oxide-mediated vasodilator response to mental stress in the forearm circulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Relation of endothelial nitric oxide synthase gene to plasma nitric oxide level, endothelial function, and blood pressure in African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Impact of beta-adrenoceptor antagonists on myofilament calcium sensitivity of rabbit and human myocardium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Nebivolol inhibits vascular smooth muscle cell proliferation by mechanisms involving nitric oxide but not cyclic GMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Atenolol in hypertension: is it a wise choice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case–control studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007310378

21 January 2018

Identifiers

DOI

10.1177/0091270007310378

1 reference

17 August 2017

1 reference

PubMed ID

18083889